mRNA UCV Consortium for development of the mRNA Universal Coronavirus Vaccine by NORVAX UK (ECAM Vaccines Limited)

About The mRNA UCV Consortium

NORVAX UK Limited founded the mRNA UCV Consortium with the mission to develop and manufacture the mRNA Universal Coronavirus Vaccine (UCV) at industrial scale for COVAX Markets and HIC Markets for delivery in 2022/23 on Advance Purchase Agreements (APA) by sponsors, governments and industry customers. The vision of mRNA UCV Consortium is to help end the COVID-19 pandemic and to stimulate and support pandemic preparedness for future outbreaks.

The fact is, no one is truly safe until everyone is safe.

The goal of the mRNA Universal Coronavirus Vaccine (mRNA UCV) in development by Norvax UK (ECAM Vaccines Limited) with Norsk Vaksinefabrikk (Norvax AS) and the mRNA UCV Consortium is to help solve the urgent global need for a one-time COVID-19 booster to save lives and help to end the COVID-19 pandemic and to support mRNA vaccine innovation for future pandemic preparedness.

LEARN MORE